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Abstract
Background: Colorectal cancer (CRC) is the second leading cause of cancer death in developed countries. Familial
aggregation in CRC is also important outside syndromic forms and, in this case, a polygenic model with several
common low-penetrance alleles contributing to CRC genetic predisposition could be hypothesized. Mucins and
GALNTs (N-acetylgalactosaminyltransferase) are interesting candidates for CRC genetic susceptibility and have not
been previously evaluated. We present results for ten genetic variants linked to CRC risk in previous studies
(previously identified category) and 18 selected variants from the mucin gene family in a case-control association
study from the Spanish EPICOLON consortium.
Methods: CRC cases and matched controls were from EPICOLON, a prospective, multicenter, nationwide Spanish
initiative, comprised of two independent stages. Stage 1 corresponded to 515 CRC cases and 515 controls, whereas
stage 2 consisted of 901 CRC cases and 909 controls. Also, an independent cohort of 549 CRC cases and 599
controls outside EPICOLON was available for additional replication. Genotyping was performed for ten previously
identified SNPs in ADH1C, APC, CCDN1, IL6, IL8, IRS1, MTHFR, PPARG, VDR and ARL11, and 18 selected variants in the
mucin gene family.
Results: None of the 28 SNPs analyzed in our study was found to be associated with CRC risk. Although four SNPs
were significant with a P-value < 0.05 in EPICOLON stage 1 [rs698 in ADH1C (OR = 1.63, 95% CI = 1.06-2.50, P-value
= 0.02, recessive), rs1800795 in IL6 (OR = 1.62, 95% CI = 1.10-2.37, P-value = 0.01, recessive), rs3803185 in ARL11 (OR
= 1.58, 95% CI = 1.17-2.15, P-value = 0.007, codominant), and rs2102302 in GALNTL2 (OR = 1.20, 95% CI = 1.00-1.44,
P-value = 0.04, log-additive 0, 1, 2 alleles], only rs3803185 achieved statistical significance in EPICOLON stage 2 (OR
= 1.34, 95% CI = 1.06-1.69, P-value = 0.01, recessive). In the joint analysis for both stages, results were only
significant for rs3803185 (OR = 1.12, 95% CI = 1.00-1.25, P-value = 0.04, log-additive 0, 1, 2 alleles) and borderline
significant for rs698 and rs2102302. The rs3803185 variant was not significantly associated with CRC risk in an
external cohort (MCC-Spain), but it still showed some borderline significance in the pooled analysis of both cohorts
(OR = 1.08, 95% CI = 0.98-1.18, P-value = 0.09, log-additive 0, 1, 2 alleles).
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Conclusions: ARL11, ADH1C, GALNTL2 and IL6 genetic variants may have an effect on CRC risk. Further validation
and meta-analyses should be undertaken in larger CRC studies.
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Background
Colorectal cancer (CRC) is the second leading cause of
cancer death in developed countries [1]. Familial adeno-
matous polyposis and Lynch syndrome are the most fre-
quent hereditary CRC syndromes with a more
aggressive presentation, earlier onset and strong familial
aggregation. However, they only correspond to a minor-
ity of the total CRC burden (~5%). Most genetic compo-
nents involved in these less frequent hereditary forms
were successfully identified in the past two decades and
they correspond to rare, highly penetrant alleles that
predispose to CRC. Genetic association analyses have
been the strategy to identify predisposing CRC alleles in
the last decade, firstly by studying a small number of
such variants or single nucleotide polymorphisms (SNP)
using candidate-gene approaches [2], and lately with an
unbiased strategy by genome-wide association studies
(GWAS) [3,4].
From the EPICOLON consortium [5], several genetic
association candidate-gene efforts have been pursued
since 2005 aiming to identify genetic susceptibility var-
iants for CRC. In this manner, SNPs/genes were selected
to be studied from the previously identified category
(variants linked to CRC risk in previous studies), from
human syntenic CRC susceptibility regions identified in
mouse, from the CRC carcinogenesis-related pathways
Wnt and BMP, from regions 9q22 and 3q22 with posi-
tive linkage in CRC families, and from the mucin gene
family [6-8]
SNPs in genes selected in the previously identified
category (ADH1C, APC, CCDN1, IL6, IL8, IRS1,
MTHFR, PPARG, VDR and ARL11) have been analyzed
in previous independent genetic association studies and
they are a priori attractive candidates for genetic sus-
ceptibility to CRC [6,9-24]. The expression of most
genes in this category are altered in CRC and they
appear to be involved in important processes for CRC
risk such as hereditary CRC (APC), alcohol metabolism
(ADH1C), inflammation (IL6, IL8), cell cycle regulation
(CCDN1), energy balance (IRS1, PPARG), methylation
(MTHFR), vitamin D (VDR), and the RAS superfamily
(ARL11). On the other hand, mucins are protein consti-
tuents of the mucous barrier that protects human
epithelia from adverse conditions, and they are highly
glycosylated by GALNT proteins. Mucins and GALNTs,
members of the mucin gene family, can be found
deregulated in CRC and other neoplasms and, although
also interesting candidates, they have not been pre-
viously evaluated for CRC genetic susceptibility [25].
Here, we report results from a case-control association
study for CRC risk in the EPICOLON cohort for pre-
viously identified SNPs in ADH1C, APC, CCDN1, IL6,
IL8, IRS1, MTHFR, PPARG, VDR and ARL11, and
selected variants within the mucin gene family.
Methods
Study populations
Studied subjects were mainly from EPICOLON, a pro-
spective, multicenter, nationwide Spanish initiative
http://www.aegastro.es/aeg/ctl_servlet?_f=16&grupo=4
[5], comprised of two stages (2000-2001 and 2006-2008),
where CRC cases and matched healthy controls were
collected. DNA samples were extracted as previously
described [6,7]. EPICOLON stage 1 corresponded to
515 CRC cases and 515 controls, whereas EPICOLON
stage 2 consisted of 901 CRC cases and 909 controls.
Additionally, an independent cohort of 549 CRC cases
and 599 controls (MCC-Spain; http://www.creal.cat) was
available for further replication of putative positive hits
in EPICOLON. Cases and controls were matched for
sex and age (± 5 years) and controls were negative for
personal and family cancer history. All samples were
obtained with informed consent reviewed by the ethical
board of the corresponding hospital.
Gene and SNP selection
Selected SNPs were included in the previously identified
category if they corresponded to genetic variants linked
to CRC risk by previously published independent stu-
dies, or in the mucin gene family if located on genes
encoding for mucins and GALNT proteins. Mucins are
protein constituents of the mucous barrier highly glyco-
sylated by GALNT proteins. One relevant previously
identified SNP was studied in each of the following
genes: ADH1C, APC, CCDN1, IL6, IL8, IRS1, MTHFR,
PPARG, VDR and ARL11. For the mucin gene family, 1-
2 SNPs were selected from each of the following genes:
MUC7, MUC12, MUC13, MUC15, MUC16, MUC17,
MUC19, MUC21, GALNT1, GALNTL2, GALNT10,
GALNT14, GALNT4 and OVGP1. Mucin gene selection
did not intentionally include GALTN12. This gene is
located on the 9q22 region and it was studied in our
candidate-gene approach for regions with positive link-
age in CRC families (Abulí et al., manuscript in
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preparation). SNP selection in the mucin gene family
was performed using Pupasuite, a web tool for the selec-
tion of genetic variants with potential phenotypic effect
(pupasuite.bioinfo.cipf.es) [26]. SNPs were always priori-
tized if they were coding, evolutionary conserved in
mouse and SNP minor allele frequency (MAF) was
above 5%. Other selected SNPs with a putative regula-
tory effect were in promoter, intronic or 3’-UTR regions.
A complete list of SNP and genes analyzed in the pre-
sent study is detailed in Table 1.
High-throughput genotyping in EPICOLON cohorts
was performed according to manufacturer’s instruc-
tions with the TaqMan allelic discrimination and
SNPlex™ systems (Applied Biosystems, Foster City,
USA), and single-base primer extension chemistry
matrix-assisted laser desorption/ionization time-of-
flight mass spectrometry (MALDI-TOF MS) genotyp-
ing platform (Sequenom Inc., San Diego, USA). Geno-
typing in the MCC-Spain cohort was performed using
the VeraCode technology (Illumina, San Diego, USA).
Genotyping was performed at the Santiago de Com-
postela and Barcelona nodes of the Spanish National
Genotyping Centre http://www.cegen.org, and at the
Genome Analysis Platform of the CIC-BioGUNE
http://www.cicbiogune.es.
Statistical methods
As quality control, genotyping success was set above
90% for SNPs. Allelic frequency description and Hardy-
Weinberg equilibrium test were performed using SNPa-
tor, a web-based tool offered by the Bioinformatics divi-
sion of the Spanish National Genotyping Centre
(bioinformatica.cegen.upf.es) [27]. All SNPs analyzed
had a genotype success rate > 90%. The genotype fre-
quencies of all variants in the control population fitted
the Hardy-Weinberg equilibrium (P > 0.01), supporting
absence of genotyping artifacts. There was no sign of
underlying population stratification in EPICOLON as
Table 1 SNPs genotyped in EPICOLON from the previously identified category and the mucin gene family to evaluate
their implication in CRC genetic susceptibility.
Gene SNP ID Chr Position* Category SNP type Alleles
MTHFR rs1801133 1 11856378 Previously identified Missense (A222V) C/T
IRS1 rs1801278 2 227660544 Previously identified Missense (G971R) A/G
PPARG rs1801282 3 12393125 Previously identified Missense (P12A) C/G
IL8 rs4073 4 74606024 Previously identified Promoter A/T
ADH1C rs698 4 100260789 Previously identified Missense (I350V) A/G
APC rs459552 5 112176756 Previously identified Missense (V1822D) A/T
IL6 rs1800795 7 22766645 Previously identified Promoter C/G
CCDN1 rs9344 11 69462910 Previously identified Synonymous (P241P) A/G
VDR rs2228570 12 48272895 Previously identified Missense (M1T) C/T
ARL11 rs3803185 13 50205025 Previously identified Missense (C158R) A/G
OVGP1 rs10067 1 111957311 Mucin family Missense (H604Q) C/G
GALNT14 rs2288101 2 31135184 Mucin family Missense (Q469K) A/C
GALNT14 rs11676188 2 31352788 Mucin family Intronic C/G
GALNTL2 rs2102302 3 16215650 Mucin family Promoter A/G
MUC13 rs12732 3 124624568 Mucin family 3’-UTR C/T
MUC13 rs4679392 3 124646594 Mucin family Missense (I99T) A/G
MUC7 rs6826961 4 71346701 Mucin family Missense (N80K) C/G
GALNT10 rs6580076 5 153783753 Mucin family Synonymous (A382A) C/T
GALNT10 rs2277937 5 153799165 Mucin family 3’-UTR C/T
MUC21 rs1634730 6 30954245 Mucin family Missense (V98A) C/T
MUC12 rs11766125 7 100648117 Mucin family Missense (T4758R) C/G
MUC17 rs4729656 7 100701610 Mucin family 3’-UTR A/T
MUC15 rs15783 11 26586801 Mucin family Missense (T229I) A/G
MUC15 rs11029621 11 26596998 Mucin family 3’ near gene A/G
MUC19 rs2933353 12 40857943 Mucin family Missense (G1803A) A/C
GALNT4 rs2230283 12 89916811 Mucin family Missense (V506I) A/G
GALNT1 rs17647532 18 33234072 Mucin family Promoter C/T
MUC16 rs1862458 19 9069792 Mucin family Missense (S5885F) A/G
SNP ID, single nucleotide polymorphism identification.
Chr: Chromosome; UTR: untranslated region. *According to NCBI build 37.1 available at http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp.
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tested by an independent study [7]. Genotype analysis
was carried out using the SNPassoc R library [28]. Inter-
group comparisons of genotype frequency differences
were performed by regression analysis for codominant,
dominant, recessive and log-additive models of inheri-
tance. We estimated the crude odds ratio (OR) and
their 95% confidence intervals (95% CIs). As expected,
results did not change after sex and age adjustment.
The best genetic or inheritance model was selected
using the Akaike information criteria. To address the
issue of multiple testing, we used Bonferroni correction
(P = 0.0125 for four SNPs). Study power was estimated
with CaTS software [29].
Results
Twenty-eight SNPs, ten from the previously identified
category and 18 from the mucin gene family, were suc-
cessfully genotyped in EPICOLON stage 1. Results in
EPICOLON stage 1 are shown in Additional File 1. Four
SNPs were significant with a P-value < 0.05 in any of
the tested inheritance models: rs698 in ADH1C (OR =
1.63, 95% CI = 1.06-2.50, P-value = 0.02, recessive, AA-
AG vs GG), rs1800795 in IL6 (OR = 1.62, 95% CI =
1.10-2.37, P-value = 0.01, recessive, GG-GC vs CC),
rs3803185 in ARL11 (OR = 1.58, 95% CI = 1.17-2.15, P-
value = 0.007, codominant, GG vs AG vs GG), and
rs2102302 in GALNTL2 (OR = 1.20, 95% CI = 1.00-
1.44, P-value = 0.04, log-additive 0, 1, 2 alleles).
In the EPICOLON stage 1 cohort, a liberal P-value
threshold (P-value < 0.05) was used to avoid false-nega-
tive results. We then validated statistically-significant
stage 1 results by replicating them in another indepen-
dent CRC cohort (EPICOLON stage 2). Further replica-
tion in stage 2 was performed only for significant SNPs
in stage 1. Results for rs698, rs1800795, rs3803185, and
rs2102302 in EPICOLON stage 2 are shown in Addi-
tional File 2. Only rs3803185 maintained statistical sig-
nificance in stage 2 (OR = 1.34, 95% CI = 1.06-1.69, P-
value = 0.01, recessive model, AA-AG vs GG). In order
to improve statistical power, results for EPICOLON
stages 1 and 2 were also analyzed jointly for these four
SNPs. Results were only significant for rs3803185 (OR =
1.12, 95% CI = 1.00-1.25, P-value = 0.04, log-additive 0,
1, 2 alleles) and borderline significant for rs698 and
rs2102302 (Table 2).
In order to further investigate rs3803185, we were able
to genotype it additionally outside EPICOLON in a
cohort from a Spanish multicase-control population
study for common neoplasms (MCC-Spain). This var-
iant was not significantly associated with CRC risk in
this independent cohort. Pooled analysis for rs3803185
in the EPICOLON and MCC-Spain cohorts still showed
borderline significance (OR = 1.08, 95% CI = 0.98-1.18,
P-value = 0.09, log-additive 0, 1, 2 alleles).
Table 2 SNPassoc results for previously identified and
mucin SNPs in EPICOLON cohorts.
EPICOLON stages 1+2 (1,416 CRC cases and 1,424 controls)
ADH1C
rs698 Controls % Cases % OR lower upper P-value
Codominant
A/A 629 46.1 616 44.2 1.00 0.13565
A/G 610 44.7 620 44.4 1.04 0.89 1.22
G/G 125 9.2 159 11.4 1.30 1.00 1.69
Dominant
A/A 629 46.1 616 44.2 1.00 0.29181
A/G-G/G 735 53.9 779 55.8 1.08 0.93 1.26
Recessive
A/A-A/G 1239 90.8 1236 88.6 1.00 0.05243
G/G 125 9.2 159 11.4 1.28 1.00 1.63
Log-Additive
0, 1, 2 1364 49.4 1395 50.6 1.10 0.98 1.24 0.09043
IL6
rs1800795 Controls % Cases % OR lower upper P-value
Codominant
G/G 593 42.7 586 41.7 1.00 0.7950
G/C 623 44.9 635 45.2 1.03 0.88 1.21
C/C 172 12.4 184 13.1 1.08 0.85 1.37
Dominant
G/G 593 42.7 586 41.7 1.00 0.5862
G/C-C/C 795 57.3 819 58.3 1.04 0.90 1.21
Recessive
G/G-G/C 1216 87.6 1221 86.9 1.00 0.5763
C/C 172 12.4 184 13.1 1.07 0.85 1.33
log-Additive
0, 1, 2 1388 49.7 1405 50.3 1.04 0.93 1.16 0.5034
ARL11
rs3803185 Controls % Cases % OR lower upper P-value
Codominant
A/A 359 26.9 301 23.7 1.00 0.12263
A/G 686 51.4 666 52.4 1.15 0.95 1.39
G/G 289 21.7 304 23.9 1.26 1.01 1.57
Dominant
A/A 359 26.9 301 23.7 1.00 0.06417
A/G-G/G 975 73.1 970 76.3 1.18 0.99 1.41
Recessive
A/A-A/G 1045 78.3 967 76.1 1.00 0.15480
G/G 289 21.7 304 23.9 1.14 0.95 1.37
log-Additive
0, 1, 2 1334 51.2 1271 48.8 1.12 1.00 1.25 0.04338
GALNTL2
rs2102302 Controls % Cases % OR lower upper P-value
Codominant
A/A 579 42.1 538 39.0 1.00 0.16056
A/G 607 44.1 624 45.3 1.11 0.94 1.30
Abulí et al. BMC Cancer 2011, 11:339
http://www.biomedcentral.com/1471-2407/11/339
Page 4 of 8
Associations of rs698, rs1800795, rs3803185 and
rs2102302 were also evaluated in 2 cohorts described in
a previous GWAS [30], either by checking the original
variant or a proxy SNP highly correlated with it (r2 >
0.7) (Table 3). Interestingly, rs3803185 showed again
significance in one of the GWAS (P = 0.03). However, it
should be commented that weak associations observed
in our study would have not been present if Bonferroni
correction for multiple testing was applied and, there-
fore, they should be considered as not statistically
significant.
Discussion
Ten previously identified SNPs in ADH1C, APC,
CCDN1, IL6, IL8, IRS1, MTHFR, PPARG, VDR and
ARL11, and 18 selected variants in the mucin gene
family were evaluated with a genetic association strategy.
CRC cases and matched controls collected in two inde-
pendent stages within the EPICOLON consortium were
genotyped in order to evaluate its potential association
with CRC risk. Mucins and GALNTs, members of the
mucin gene family, have not been previously evaluated
for CRC genetic susceptibility.
Significant results for previously identified SNPs in
independent cohorts regarding CRC risk were previously
reported for APC [11,12], CCDN1 [13,14], IL6 and IL8
[15,16], IRS1 [17], MTHFR [18-20], PPARG [21], and
VDR [22,23]. Remarkably, variants in MTHFR and
CCDN1 were additionally supported by meta-analyses of
several individual studies [31]. However, none of them
was confirmed in our cohort.
In our study, four SNPs were significant in EPICO-
LON stage 1 (rs698 in ADH1C, rs1800795 in IL6,
rs3803185 in ARL11, and rs2102302 in GALNTL2), but
only rs3803185 achieved statistical significance in EPI-
COLON stage 2. In the joint analysis for both stages,
results were only significant for rs3803185 and border-
line significant for rs698 and rs2102302. The rs3803185
variant was not significantly associated with CRC risk in
an external cohort (MCC-Spain), but it still showed
some borderline significance in the pooled analysis of
both cohorts.
ARL11, also known as ARLTS1 (ADP-ribosylation fac-
tor-like tumor suppressor gene 1), is a tumor suppressor
gene that belongs to the ARF family of the Ras super-
family of small GTPases that are known to be involved
in multiple regulatory pathways altered in human carci-
nogenesis. It has been suggested that ARL11 SNPs, espe-
cially rs3803185, may act as low penetrance variants in
several neoplasms including CRC [6,24,32]. The ADH1C
gene encodes for class I alcohol dehydrogenase, gamma
subunit, which is a member of the alcohol dehydrogen-
ase family. Members of this enzyme family metabolize a
wide variety of substrates, including ethanol. There is a
noticeable association between alcohol consumption and
CRC risk [33], and it is plausible that this association
could also be modified by germline variants in enzymes
that metabolize ethanol. GALNTL2 (UDP-N-acetyl-
alpha-D-galactosamine:polypeptide N-acetylgalactosami-
nyltransferase-like 2), also known as GALNT15, is ubi-
quitously expressed in human tissues [34]. This gene
has never been investigated in CRC susceptibility and it
has only been reported to be studied as a genetic factor
involved in longevity [35]. Chronic inflammation is in
the etiology of CRC and release of large amount of cyto-
kines and growth factors may influence the carcinogen-
esis process. The IL6 (interleukin 6) gene, among others,
has been analyzed in previous independent genetic asso-
ciation studies and it is an a priori attractive candidate
for genetic susceptibility to CRC [15,16].
Finally, as limitations of our study, it should be com-
mented that our cohort sample size may probably be
Table 2 SNPassoc results for previously identified and
mucin SNPs in EPICOLON cohorts. (Continued)
G/G 189 13.7 217 15.7 1.23 0.98 1.55
Dominant
A/A 579 42.1 538 39.0 1.00 0.0971
A/G-G/G 796 57.9 841 61.0 1.14 0.98 1.32
Recessive
A/A-A/G 1186 86.3 1162 84.3 1.00 0.14317
G/G 189 13.7 217 15.7 1.17 0.95 1.45
log-Additive
0, 1, 2 1375 49.9 1379 50.1 1.11 1.00 1.24 0.0558
Significant P-values (< 0.05) are highlighted in bold.
OR, odds ratio.
Table 3 Association results for four selected SNPs evaluated in two external GWAS (CORGI and VQ58), either by
checking the original variant or a proxy SNP highly correlated with it (r2 > 0).
Present in I5? Present in I3? Proxy r2 and D’ P-value (CORGI) P-value (VQ58)
rs698 no no rs1789924 1.000 1.000 0.1806 0.1658
rs1800795 no no rs1554606 0.868 0.932 0.1743 0.3346
rs3803185 no no rs4942859 0.716 1.000 0.5943 0.03525
rs2102302 no no rs2730351 0.853 1.000 0.1447 0.4666
Significant P-values (< 0.05) are highlighted in bold.
I5, Illumina HumanHap550; I3 Illumina HumanHap300.
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not large enough to reach stronger conclusions for the
analyzed variants. However, our study (1,416 CRC cases
and 1,424 controls for the EPICOLON cohorts) had an
estimated 80% power to detect an OR as low as 1.3 with
a MAF of 0.30, and 1.34 for a MAF down to 0.20,
assuming a log-additive model and a = 0.05. Also, since
we did not follow a GWAS strategy, our results apply
only for the selected SNPs. Nevertheless, gene/SNP
selection was biased to include those with previously
published positive association results for CRC risk or
those mucin SNPs with a putative functional effect.
In summary, none of the 28 SNPs analyzed in our
study could be associated with CRC risk. However, var-
iants in ARL11, ADH1C, GALNTL2 and IL6 may have
an effect on CRC risk. Mucins and GALNTs, included
in the mucin gene family, have been found deregulated
in CRC and other neoplasms, and they are interesting
candidates for CRC genetic susceptibility [27]. Since
they have not been previously evaluated and despite our
mostly negative results, we consider that genetic varia-
tion in the mucin gene family should be further
explored in larger CRC cohorts in order to draw more
solid conclusions. Also, additional case-control studies
in larger CRC cohorts and meta-analyses could be useful
to confirm or refute the role of ARL11, ADH1C,
GALNTL2 and IL6 variants in CRC susceptibility.
Conclusions
None of the 28 SNPs analyzed in our study could be
associated with CRC risk. However, ARL11, ADH1C,
GALNTL2 and IL6 genetic variants may have an effect
on CRC risk. Further validation and meta-analyses
should be undertaken in larger CRC cohorts.
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highlighted in bold if significant (P < 0.05).
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